Exelixis throws in the towel on early-stage liver cancer after final readout shows OS flop
The door to a label expansion for Exelixis’ Cabometyx is now fully shut.
Exelixis kept a sliver of hope — however slim — back in the summer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
